Alkermes is a fully integrated, worldwide biopharmaceutical company focused on applying its scientific expertise and proprietary technologies in the development of innovative medicines to improve patient outcomes. Headquartered in Dublin, Ireland, the company has a diversified portfolio including more than 20 commercial drug products and an extensive clinical pipeline of product candidates that address central nervous system disorders like addiction, schizophrenia and depression. The company has an R&D center in Waltham, Mass.; a research and manufacturing facility in Athlone, Ireland; and manufacturing facilities in Gainesville, Ga., and Wilmington, Ohio. For more information, visit the company’s Web site at www.alkermes.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: